RespireRx Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
RespireRx Pharmaceuticals Inc. - overview
Established
1987
Location
Glen Rock, NJ, US
Primary Industry
Biotechnology
About
Based in New Jersey, US, and founded in 1987, RespireRx Pharmaceuticals Inc. operates as a provider of revolutionary treatments to treat disorders caused by neuronal signaling disruption, treating conditions such as obstructive sleep apnea and epilepsy. The firm trades on the Nasdaq under the ticker symbol RSPI. The company provides a wide range of pharmaceutical cannabinoid products under ResolutionRx, repurposing dronabinol for obstructive sleep apnea (OSA) treatment.
Additionally, the firm offers neuromodulators, including AMPAkines and GABAkines, under the EndeavourRx platform. Moreover, the firm offers treatments that target disorders caused by disruptions in neuronal signaling, addressing conditions such as attention deficit hyperactivity disorder (ADHD), epilepsy, chronic pain, and spinal cord injury (SCI).
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.respirerx.com/
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.